-
Something wrong with this record ?
Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine
DS. Dhanjal, R. Singh, V. Sharma, E. Nepovimova, V. Adam, K. Kuca, C. Chopra
Language English Country United Arab Emirates
Document type Journal Article, Review
Grant support
2217/2022-2023
Excellence project PrF UHK
00179906
Ministry of Health project MHCZ - DRO (UHHK)
- MeSH
- Genetic Engineering MeSH
- Induced Pluripotent Stem Cells metabolism cytology MeSH
- Humans MeSH
- Cellular Reprogramming * MeSH
- Regenerative Medicine * MeSH
- Tissue Engineering MeSH
- Developmental Biology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
The foundations of cell reprogramming were laid by Yamanaka and co-workers, who showed that somatic cells can be reprogrammed into pluripotent cells (induced pluripotency). Since this discovery, the field of regenerative medicine has seen advancements. For example, because they can differentiate into multiple cell types, pluripotent stem cells are considered vital components in regenerative medicine aimed at the functional restoration of damaged tissue. Despite years of research, both replacement and restoration of failed organs/ tissues have remained elusive scientific feats. However, with the inception of cell engineering and nuclear reprogramming, useful solutions have been identified to counter the need for compatible and sustainable organs. By combining the science underlying genetic engineering and nuclear reprogramming with regenerative medicine, scientists have engineered cells to make gene and stem cell therapies applicable and effective. These approaches have enabled the targeting of various pathways to reprogramme cells, i.e., make them behave in beneficial ways in a patient-specific manner. Technological advancements have clearly supported the concept and realization of regenerative medicine. Genetic engineering is used for tissue engineering and nuclear reprogramming and has led to advances in regenerative medicine. Targeted therapies and replacement of traumatized , damaged, or aged organs can be realized through genetic engineering. Furthermore, the success of these therapies has been validated through thousands of clinical trials. Scientists are currently evaluating induced tissue-specific stem cells (iTSCs), which may lead to tumour-free applications of pluripotency induction. In this review, we present state-of-the-art genetic engineering that has been used in regenerative medicine. We also focus on ways that genetic engineering and nuclear reprogramming have transformed regenerative medicine and have become unique therapeutic niches.
Biomedical Research Center University Hospital Hradec Kralove Hradec Kralove 50005 Czech Republic
Head of Bioinformatic Division NMC Genetics India Pvt Ltd Gurugram India
School of Bioengineering and Biosciences Lovely Professional University Phagwara Punjab India
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014608
- 003
- CZ-PrNML
- 005
- 20240905133338.0
- 007
- ta
- 008
- 240725s2024 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/0929867330666230503144619 $2 doi
- 035 __
- $a (PubMed)37138422
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Dhanjal, Daljeet Singh $u School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India
- 245 10
- $a Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine / $c DS. Dhanjal, R. Singh, V. Sharma, E. Nepovimova, V. Adam, K. Kuca, C. Chopra
- 520 9_
- $a The foundations of cell reprogramming were laid by Yamanaka and co-workers, who showed that somatic cells can be reprogrammed into pluripotent cells (induced pluripotency). Since this discovery, the field of regenerative medicine has seen advancements. For example, because they can differentiate into multiple cell types, pluripotent stem cells are considered vital components in regenerative medicine aimed at the functional restoration of damaged tissue. Despite years of research, both replacement and restoration of failed organs/ tissues have remained elusive scientific feats. However, with the inception of cell engineering and nuclear reprogramming, useful solutions have been identified to counter the need for compatible and sustainable organs. By combining the science underlying genetic engineering and nuclear reprogramming with regenerative medicine, scientists have engineered cells to make gene and stem cell therapies applicable and effective. These approaches have enabled the targeting of various pathways to reprogramme cells, i.e., make them behave in beneficial ways in a patient-specific manner. Technological advancements have clearly supported the concept and realization of regenerative medicine. Genetic engineering is used for tissue engineering and nuclear reprogramming and has led to advances in regenerative medicine. Targeted therapies and replacement of traumatized , damaged, or aged organs can be realized through genetic engineering. Furthermore, the success of these therapies has been validated through thousands of clinical trials. Scientists are currently evaluating induced tissue-specific stem cells (iTSCs), which may lead to tumour-free applications of pluripotency induction. In this review, we present state-of-the-art genetic engineering that has been used in regenerative medicine. We also focus on ways that genetic engineering and nuclear reprogramming have transformed regenerative medicine and have become unique therapeutic niches.
- 650 12
- $a regenerativní lékařství $7 D044968
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a přeprogramování buněk $7 D065150
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a vývojová biologie $7 D015509
- 650 _2
- $a genetické inženýrství $7 D005818
- 650 _2
- $a tkáňové inženýrství $7 D023822
- 650 _2
- $a indukované pluripotentní kmenové buňky $x metabolismus $x cytologie $7 D057026
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Singh, Reena $u School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India
- 700 1_
- $a Sharma, Varun $u Head of Bioinformatic Division, NMC Genetics India Pvt. Ltd., Gurugram, India
- 700 1_
- $a Nepovimova, Eugenie $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, 50003, Czech Republic $1 https://orcid.org/000000030281246X $7 xx0224758
- 700 1_
- $a Adam, Vojtech $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, CZ 613 00, Czech Republic $u Central European Institute of Technology, Brno University of Technology, Purkynova 123, Brno, CZ-612 00, Czech Republic
- 700 1_
- $a Kuca, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, 50003, Czech Republic $u Biomedical Research Center, University Hospital Hradec Kralove, Hradec Kralove, 50005, Czech Republic $1 https://orcid.org/0000000196641109 $7 xx0041831
- 700 1_
- $a Chopra, Chirag $u School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India
- 773 0_
- $w MED00001274 $t Current medicinal chemistry $x 1875-533X $g Roč. 31, č. 13 (2024), s. 1646-1690
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37138422 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133332 $b ABA008
- 999 __
- $a ok $b bmc $g 2144027 $s 1226474
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 31 $c 13 $d 1646-1690 $e - $i 1875-533X $m Current medicinal chemistry $n Curr Med Chem $x MED00001274
- GRA __
- $a 2217/2022-2023 $p Excellence project PrF UHK
- GRA __
- $a 00179906 $p Ministry of Health project MHCZ - DRO (UHHK)
- LZP __
- $a Pubmed-20240725